Back to Results
First PageMeta Content
Lung cancer / Clinical medicine / Cancer / Tyrosine kinase inhibitors / Boehringer Ingelheim / Health / T790M / Protein kinase inhibitor / Epidermal growth factor receptor / Non-small-cell lung carcinoma / Targeted therapy


ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced
Add to Reading List

Document Date: 2015-11-24 01:50:17

Open Document

File Size: 225,61 KB

Share Result on Facebook
UPDATE